Aktuellt
SENASTE
Earlier today, Spago Nanomedical provided a study update on the Australian-based Tumorad-01 (I/IIa) trial. Two males with metastatic castration-resistant prostate cancer (mCRPC) have completed the initial dosing without any serious adverse events (SEAs), and two female patients with different tumour types have been included and identified, respectively.
LÄS MER
